Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Pinede L, Ninet J, Duhaut P et al for the Investigators of the 'Durée Optimale du Traitement Antivitamines K' (DOTAVK) study. Circulation 2001; 103: 2453-60

Autor: S S, Anand

Publikováno v: Vascular medicine (London, England). 6(4)

Is anticoagulant treatment for calf vein thrombosis for 6 weeks duration associated with acceptable recurrence and safety outcomes? Is anticoagulant therapy for 3 months duration for proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) asso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1ee4c26f5d957763c8b0fc02d022f46c
https://pubmed.ncbi.nlm.nih.gov/11958396

Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis.

Autor: Khan F; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Rahman A; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada., Tritschler T; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Carrier M; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Kearon C; The Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Canada., Weitz JI; The Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Canada., Schulman S; The Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.; Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia., Couturaud F; Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France., Becattini C; Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, Perugia, Italy., Agnelli G; Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, Perugia, Italy., Brighton TA; Department of Haematology, Prince of Wales Hospital, Sydney, Australia., Lensing AWA; Bayer AG, Wuppertal, Germany., Pinede L; Department of Internal Medicine, Infirmerie Protestante, Caluire - Lyon, France., Parpia S; Departments of Oncology, and Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Geersing GJ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Takada T; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Bradbury CA; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Andreozzi GM; Angiology Care Unit, University of Padova, Padova, Italy., Palareti G; Arianna Foundation on Anticoagulation, Bologna, Italy., Prandoni P; Arianna Foundation on Anticoagulation, Bologna, Italy., Buller HR; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands., Mallick R; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Hutton B; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Thavorn K; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Le Gal G; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada., Rodger MA; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.; Department of Medicine, McGill University, Montreal, Canada., Fergusson DA; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Publikováno v: Thrombosis and haemostasis [Thromb Haemost] 2022 Jul; Vol. 122 (7), pp. 1186-1197. Date of Electronic Publication: 2021 Nov 09.

Durée du traitement anticoagulant oral dans la TVP des membres inférieurs

Autor: Pinède, L.

Publikováno v: In Annales de cardiologie et d'angeiologie 2002 51(3):158-163

Life-Threatening Conditions and Preoperative Complications Associated with Cardiac Neoplasm Do Not Affect Surgical Outcomes or Mortality.

Autor: Suzuki, Kenji¹ (AUTHOR) suzuki@nms.ac.jp, Sakamoto, Shun-Ichiro¹ (AUTHOR), Hiromoto, Atsushi¹ (AUTHOR), Maeda, Motohiro¹ (AUTHOR), Yamaguchi, Takako² (AUTHOR), Yamada, Naoki³ (AUTHOR), Ueda, Hitomi³ (AUTHOR), Matsuyama, Takayoshi³ (AUTHOR), Osaka, Shin-Ichi³ (AUTHOR), Ishii, Yosuke³ (AUTHOR)

Publikováno v: Journal of Clinical Medicine. Sep2024, Vol. 13 Issue 18, p5532. 9p.

Thirty-five years of single-center experience in cardiac myxoma surgery and related postoperative complications.

Autor: Grudzien, Grzegorz¹, Batko, Jakub¹, Olejek, Wojciech¹, Brzezinski, Maciej², Kapelak, Boguslaw¹, Bartus, Krzysztof¹ krzysztofbartus@gmail.com

Publikováno v: Polish Journal of Thoracic & Cardiovascular Surgery / Kardiochirurgia i Torakochirurgia Polska. 2024, Vol. 21 Issue 3, p133-136. 4p.